Verici Dx Plc
LSE:VRCI
Verici Dx Plc
Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 8 full-time employees. The company went IPO on 2020-11-03. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The firm's subsidiary is Verici Dx Inc.
Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 8 full-time employees. The company went IPO on 2020-11-03. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The firm's subsidiary is Verici Dx Inc.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
